NE compared with BIO: revenue, margins and what each company keeps, and the suppliers and customers both name

NENoble Corp plc

Mkt capRevenueRevenue

BIOBio-Rad Laboratories, Inc.

Mkt capRevenueRevenue

Compare

NENoble Corp plc

BIOBio-Rad Laboratories, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±9.4%▼−5.42%×0.57

Q2 FY26±7.6%▼−9.07%×1.20

Q1 FY26±7.9%▲+8.20%×1.04

Feb 12 '26±7.6%▼−3.36%×0.45

BIO1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+4.50%—

= impliedNE realized, solidBIO realized, hatchedOne scale, both sides: full bar = 10%× = |realized| ÷ impliedSource: market data

NENoble Corp plc

48.89▲+3.03%· post 49.00

Mkt cap$7.8BRevenue$729MQ3 FY26Revenue$3.3BFY25

BIOBio-Rad Laboratories, Inc.

372.18▼−3.18%· post 372.18

ClosedOct 30 '26

Mkt cap$10.0BRevenue$651MQ2 FY26Revenue$2.6BFY25

Compare

ClosedOct 30 '26

NENoble Corp plc

BIOBio-Rad Laboratories, Inc.

48.89▲+3.03%post 49.00

Price

372.18▼−3.18%post 372.18

$7.8B

Mkt cap

$10.0B

Q3 FY26$729M

Revenue

$651MQ2 FY26

FY25$3.3B

Revenue

$2.6BFY25

NE48.89▲+3.03%vsBIO372.18▼−3.18%ClosedOct 30 '26